All patients
Age > 65y Asian type ECOG 0 ECOG 1 metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) metastasis (lung) metastasis (lymph node ) PD-L1 < 1% PD-L1 > 1% stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mBC - TNBC - L1 - all population, atezolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpassion-130 (all population), 2018 0.86 [0.72; 1.02]
0.86 [0.72 ; 1.02 ] IMpassion-130 (all population), 2018 1 0% 902 NA not evaluable PFS (extension)detailed results IMpassion-130 (all population), 2018 0.80 [0.69; 0.92]
0.80 [0.69 ; 0.92 ] IMpassion-130 (all population), 2018 1 0% 902 NA not evaluable progression or deaths (PFS)detailed results IMpassion-130 (all population), 2018 0.80 [0.69; 0.92]
0.80 [0.69 ; 0.92 ] IMpassion-130 (all population), 2018 1 0% 902 NA not evaluable DORdetailed results IMpassion-130 (all population), 2018 0.78 [0.63; 0.97]
0.78 [0.63 ; 0.97 ] IMpassion-130 (all population), 2018 1 0% NA not evaluable objective responses (ORR)detailed results IMpassion-130 (all population), 2018 1.52 [1.17; 1.98]
1.52 [1.17 ; 1.98 ] IMpassion-130 (all population), 2018 1 0% 902 NA not evaluable AE (any grade)detailed results IMpassion-130 (all population), 2018 3.15 [0.85; 11.73]
3.15 [0.85 ; 11.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.31 [1.00; 1.70]
1.31 [1.00 ; 1.70 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable AE leading to death (grade 5)detailed results IMpassion-130 (all population), 2018 1.94 [0.48; 7.81]
1.94 [0.48 ; 7.81 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpassion-130 (all population), 2018 2.24 [1.46; 3.43]
2.24 [1.46 ; 3.43 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable SAE (any grade)detailed results IMpassion-130 (all population), 2018 1.33 [0.96; 1.84]
1.33 [0.96 ; 1.84 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable STRAE (any grade)detailed results IMpassion-130 (all population), 2018 1.82 [1.16; 2.87]
1.82 [1.16 ; 2.87 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable TRAE (any grade)detailed results IMpassion-130 (all population), 2018 1.80 [0.96; 3.39]
1.80 [0.96 ; 3.39 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable TRAE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.52 [1.15; 2.01]
1.52 [1.15 ; 2.01 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable TRAE leading to death (grade 5)detailed results IMpassion-130 (all population), 2018 2.91 [0.30; 28.05]
2.91 [0.30 ; 28.05 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
0.96 [0.06 ; 15.47 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.93 [0.17 ; 21.40 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Adrenal insufficiency AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Alopecia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.93 [0.17 ; 21.40 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Anaemia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.04 [0.48; 2.24]
1.04 [0.48 ; 2.24 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
0.96 [0.06 ; 15.47 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.72 [0.16; 3.24]
0.72 [0.16 ; 3.24 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Back pain AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 2.92 [0.59; 14.54]
2.92 [0.59 ; 14.54 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Cardiomyopathy AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Chills AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Colitis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
0.96 [0.06 ; 15.47 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Constipation AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 2.91 [0.30; 28.05]
2.91 [0.30 ; 28.05 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Cough AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.02 ; 48.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.19; 4.80]
0.96 [0.19 ; 4.80 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.85 [0.33; 2.24]
0.85 [0.33 ; 2.24 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Dizziness AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.02 ; 48.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.02 ; 48.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Dysphonia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.19; 4.80]
0.96 [0.19 ; 4.80 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.10 [0.54; 2.22]
1.10 [0.54 ; 2.22 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Headache AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.48 [0.09; 2.63]
0.48 [0.09 ; 2.63 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Hypertension AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.35 [0.11; 1.09]
0.35 [0.11 ; 1.09 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.02 ; 48.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.38; 2.45]
0.96 [0.38 ; 2.45 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.55 [0.50; 4.79]
1.55 [0.50 ; 4.79 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.55 [0.50; 4.79]
1.55 [0.50 ; 4.79 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.94 [0.35; 10.63]
1.94 [0.35 ; 10.63 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Myalgia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.64 [0.11; 3.86]
0.64 [0.11 ; 3.86 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Myopathy AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Nausea AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.60 [0.19; 1.84]
0.60 [0.19 ; 1.84 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.02 [0.63; 1.64]
1.02 [0.63 ; 1.64 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Paraesthesia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.93 [0.17 ; 21.40 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Pericarditis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.06; 57.72]
1.93 [0.06 ; 57.72 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 2.07 [1.03; 4.17]
2.07 [1.03 ; 4.17 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.16 [0.02; 1.33]
0.16 [0.02 ; 1.33 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Pneumonia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 3.27 [0.89; 11.95]
3.27 [0.89 ; 11.95 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Pneumonitis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 3.87 [0.17; 86.09]
3.87 [0.17 ; 86.09 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Pruritus AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.02; 48.73]
0.96 [0.02 ; 48.73 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 5.82 [0.29; 116.53]
5.82 [0.29 ; 116.53 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Rash AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.14; 6.88]
0.96 [0.14 ; 6.88 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Sepsis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.16 [0.01; 3.20]
0.16 [0.01 ; 3.20 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Stomatitis AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.96 [0.06; 15.47]
0.96 [0.06 ; 15.47 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 1.93 [0.17; 21.40]
1.93 [0.17 ; 21.40 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Vomiting AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 0.77 [0.21; 2.89]
0.77 [0.21 ; 2.89 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMpassion-130 (all population), 2018 5.82 [0.29; 116.53]
5.82 [0.29 ; 116.53 ] IMpassion-130 (all population), 2018 1 0% 890 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-05 10:24 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 60
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866
